NCT00083720 - Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Colorectal NeoplasmsMetastasesNeoplasm

Interventions

BIOLOGICAL

cetuximab

Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes

Trial Locations (27)

10504

ImClone Investigational Site, Armonk

11733

ImClone Investigational Site, East Setauket

17870

ImClone Investigational Site, Sellingsgrove

27710

ImClone Investigational Site, Durham

32174

ImClone Investigational Site, Ormond Beach

32256

ImClone Investigational Site, Jacksonville

32804

ImClone Investigational Site, Orlando

40202

ImClone Investigational Site, Louisville

40503

ImClone Investigational Site, Lexington

46202

ImClone Investigational Site, Indianapolis

47714

ImClone Investigational Site, Evansville

49048

ImClone Investigational Site, Kalamazoo

60031

ImClone Investigational Site, Gurnee

63110

ImClone Investigational Site, St Louis

70006

ImClone Investigational Site, Metairie

76012

ImClone Investigational Site, Arlington

76508

ImClone Investigational Site, Temple

77802

ImClone Investigational Site, Bryan

90033

ImClone Investigational Site, Los Angeles

95008

ImClone Investigational Site, Campbell

95073

ImClone Investigational Site, Soquel

02114

ImClone Investigational Site, Boston

48106-0995

ImClone Investigational Site, Ann Arbor

L1G 2B9

ImClone Investigational Site, Oshawa

K1H 1C4

ImClone Investigational Site, Ottawa

M4N 3M5

ImClone Investigational Site, Toronto

M5G 2M9

ImClone Investigational Site, Toronto